Zelis N, Devos T, Dierickx D, Janssens A, Raddoux J, Verhoef G, Delforge M
Acta Clin Belg. 2014 Apr;69(2):98-103. doi: 10.1179/0001551214Z.00000000030. Epub 2014 Mar 4.
Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for treatment of patients with relapsed/refractory multiple myeloma (MM). However, since the disease in the majority of patients will become resistant to RD, or treatment with RD needs to be discontinued due to side effects, we evaluated the combination lenalidomide, low-dose oral cyclophosphamide, with prednisone (REP) in patients with relapsed/refractory MM previously exposed to RD. For this purpose, we performed a single centre retrospective study of the efficacy of REP in 19 patients with relapsed/refractory MM. Overall response rate (partial response or better) with REP was 68% compared with 83% with RD, but with a shorter time to response with the triplet REP. Time to progression after REP was 6 months. Overall the REP regimen was better tolerated compared to RD. We conclude that the REP regimen is an effective treatment regimen for patients with relapsed/refractory MM with good tolerance, warranting further exploration in prospective randomized trials.
来那度胺（瑞复美®）联合间歇性地塞米松（RD方案）是目前复发/难治性多发性骨髓瘤（MM）患者的治疗标准方案之一。然而，由于大多数患者的疾病会对RD产生耐药性，或者因副作用需要停用RD治疗，我们评估了来那度胺、低剂量口服环磷酰胺与泼尼松联合（REP方案）用于既往接受过RD治疗的复发/难治性MM患者的疗效。为此，我们对19例复发/难治性MM患者进行了一项关于REP方案疗效的单中心回顾性研究。REP方案的总缓解率（部分缓解或更好）为68%，而RD方案为83%，但三联方案REP的缓解时间更短。REP方案后的疾病进展时间为6个月。总体而言，与RD方案相比，REP方案的耐受性更好。我们得出结论，REP方案是一种有效的治疗复发/难治性MM患者的方案，耐受性良好，值得在前瞻性随机试验中进一步探索。
